Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

NCT00310856 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Meningitis

Interventions

BIOLOGICAL: MenACWY-CRM
BIOLOGICAL: MenC-CRM
BIOLOGICAL: DTaP-Hib-IPV
BIOLOGICAL: PC7
BIOLOGICAL: MMR
BIOLOGICAL: Varicella

Sponsor

Novartis Vaccines